China Budesonide Market Overview to 2018

1
Investigation Report on China Budesonide Market,
2009-2018byChina Research and Intelligence

• Explore all reports for Life Sciences market
• _at_ http//www.chinamarketresearchreports.com/cat/li
  fe-sciences.html.

2
Investigation Report on China Budesonide Market,
2009-2018

• Asthma and allergic rhinitis are both very common
  diseases in the world today. As the global
  atmosphere becomes more and more seriously
  contaminated, incidence of these diseases
  increases year by year.
• Budesonide inhalation suspension (trade name
  "Pulmicort Respules") developed by Astra Zeneca
  was approved to market by FDA for asthma
  treatment in August 2000. It obtained import
  approval in China in November 2001. Statistics
  shows that there are more than 30 million asthma
  patients and over 0.3 billion people suffering
  from allergic rhinitis in China. According to
  CRI's investigation on certain sample hospital
  market in China, the CAGR of sales value of
  budesonide surpassed 30 from 2005 to 2010. Since
  2011, market growth has slowed down, but it still
  maintains an annual growth rate of 18.
• In April 2013, the patent protection of asthma
  drug "Pulmicort Respules" produced by Astra
  Zeneca was sentenced invalid in an U.S. regional
  court. Industry insiders think that this has
  paved the way for generic drug to occupy the
  market.
• Inquire for a discount on this report _at_
  http//www.chinamarketresearchreports.com/contacts
  /inquire-before-buy.php?name114722 .

3
Investigation Report on China Budesonide Market,
2009-2018

• According to CRI's market investigation,
  budesonide products in Chinese market are still
  mainly imported drugs from Astra Zeneca, but
  there are already some Chinese enterprises, such
  as Lunan Better Pharmaceutical Co., Ltd.,
  Humanwell Healthcare (Group) Co., Ltd. and
  Shanghai Sine Promod Pharmaceutical Co., Ltd.,
  producing budesonide APIs and finished drugs.
• On January 15, 2013 Santarus, Inc. announced that
  FDA has ratifies the usage of Uceris sustained
  release tablets in alleviating symptoms of mild 
  moderate active ulcerative colitis. Uceris is a
  new drug developed by Santarus, Inc. and Cosmo
  Technologies Limited, a subsidiary of Cosmo
  Pharmaceuticals S.p.A. This is a new oral tablet,
  and its main ingredient is budesonide.
• As Chinese economy develops and its environment
  worsens, the number of asthma and allergic
  rhinitis patients in China will continue to rise
  in the next few years. Furthermore, more
  indications may emerge in China. Consequently,
  market size of budesonide in China will therefore
  continue to grow.
• Complete report available _at_ http//www.chinamarket
  researchreports.com/114722.html .